Literature DB >> 21637136

Challenges in the management of ruptured and unruptured brainstem arteriovenous malformations: outcome after conservative, single-modality, or multimodality treatments.

Laurent Thines1, Amir R Dehdashti, Leodante da Costa, Michael Tymianski, Karel G ter Brugge, Robert A Willinsky, Michael Schwartz, M Christopher Wallace.   

Abstract

BACKGROUND: Brainstem arteriovenous malformations are challenging lesions, and benefits of treatment are uncertain.
OBJECTIVE: To study the clinical course of Brainstem arteriovenous malformations and the influence of treatments on outcome.
METHODS: We reviewed a prospective series of 31 brainstem arteriovenous malformations. Demographic, morphological, and clinical characteristics were recorded. Factors determining initial and final outcomes (modified Rankin Scale), results of treatments (cure rates, complications), and disease course were analyzed.
RESULTS: Brainstem arteriovenous malformations were symptomatic and bled in 93% and 61% of cases, respectively. Examination was abnormal and initial modified Rankin Scale score was < 3 in 71% and 86% of patients, respectively. The average follow-up time was 6.2 years, and 26% of patients rebled (5.9 %/y). Treatment modalities included conservative, radiosurgical, endovascular, surgical, and multimodality treatment in 13%, 58%, 35%, 16%, and 26% of cases, respectively. The obliteration rate was 60% overall and 39% after radiosurgery, 40% after embolization, and 75% after microsurgery, with respective complication-free cure rates of 71%, 50%, and 0%. Overall procedural mortality and morbidity were 2.3% and 18.6%, respectively. Final modified Rankin Scale score was < 3 in 77% of cases. Neurological deterioration (35%) was related to treatment complications in 74% of cases with a negative impact of surgery (P = .04), palliative embolization (odds ratio = 16), and multimodality treatments (odds ratio = 24). Radiosurgery was inversely associated with worsening (odds ratio = 0.06).
CONCLUSION: Brainstem arteriovenous malformations require individualized treatment decisions. Single-modality treatments with a reasonable chance of complete cure and low complication rate (such as radiosurgery) should be favored.

Entities:  

Mesh:

Year:  2012        PMID: 21637136     DOI: 10.1227/NEU.0b013e31822670ac

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  A challenging entity of endovascular embolization with ONYX for brainstem arteriovenous malformation: Experience from 13 cases.

Authors:  Hengwei Jin; Zhan Liu; Qing Chang; Chang Chen; Huijian Ge; Xianli Lv; Youxiang Li
Journal:  Interv Neuroradiol       Date:  2017-06-14       Impact factor: 1.610

2.  Transvenous embolization of a ruptured deep cerebral arteriovenous malformation. A technical note.

Authors:  V M Pereira; A Marcos-Gonzalez; I Radovanovic; P Bijlenga; A P Narata; J Moret; K Schaller; K O Lovblad
Journal:  Interv Neuroradiol       Date:  2013-03-04       Impact factor: 1.610

3.  The predictors of clinical outcomes in brainstem arteriovenous malformations after stereotactic radiosurgery.

Authors:  Xiaolin Ai; Jianguo Xu
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

4.  Long-term outcomes of brainstem arteriovenous malformations after different management modalities: a single-centre experience.

Authors:  Yu Chen; Ruinan Li; Li Ma; Xiangyu Meng; Debin Yan; Hao Wang; Xun Ye; Hengwei Jin; Youxiang Li; Dezhi Gao; Shibin Sun; Ali Liu; Shuo Wang; Xiaolin Chen; Yuanli Zhao
Journal:  Stroke Vasc Neurol       Date:  2020-09-14

Review 5.  Chinese Cerebrovascular Neurosurgery Society and Chinese Interventional & Hybrid Operation Society, of Chinese Stroke Association Clinical Practice Guidelines for Management of Brain Arteriovenous Malformations in Eloquent Areas.

Authors:  Mingze Wang; Yuming Jiao; Chaofan Zeng; Chaoqi Zhang; Qiheng He; Yi Yang; Wenjun Tu; Hancheng Qiu; Huaizhang Shi; Dong Zhang; Dezhi Kang; Shuo Wang; A-Li Liu; Weijian Jiang; Yong Cao; Jizong Zhao
Journal:  Front Neurol       Date:  2021-06-09       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.